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Abstract. Fibroblast growth factor receptor (FGFR)-like 
protein 1 (FGFRL1) is the most recently discovered member 
of the FGFR family. Owing to the fact that it interacts with 
FGF ligands, but lacks the intracellular tyrosine kinase domain, 
several researchers have speculated that it may function as a 
decoy receptor and exert a negative effect on cell proliferation. 
In this study, we performed overexpression experiments with 
TetOn-inducible cell clones and downregulation experiments 
with siRNA oligonucleotides, and found that FGFRL1 had 
absolutely no effect on cell growth and proliferation. Likewise, 
we did not observe any influence of FGFRL1 on ERK1/2 
activation and on the phosphorylation of 250 other signaling 
proteins analyzed by the Kinexus antibody microarray. On the 
other hand, with bacterial petri dishes, we observed a clear 
effect of FGFRL1 on cell adhesion during the initial hours 
after cell seeding. Our results suggest that FGFRL1 is a cell 
adhesion protein similar to the nectins rather than a signaling 
receptor similar to FGFR1-FGFR4.
Introduction
The family of the fibroblast growth factor receptors (FGFRs) 
comprises five transmembrane receptors that control the 
proliferation, differentiation, migration and apoptosis of most 
cell types (1,2). The classical four receptors, FGFR1 to FGFR4, 
function by binding to FGFs and heparin. This interaction trig-
gers the phosphorylation of selected residues in the intracellular 
part of the polypeptides, followed by the activation of various 
signaling cascades, such as the RAS-MAP kinase pathway, the 
phospholipase Cγ pathway and the PI3-kinase pathway.
FGFR-like protein 1 (FGFRL1) is the fifth member of the 
FGFR family (3). Similar to the classical receptors, FGFRL1 
contains three extracellular Ig-like domains and a single 
transmembrane domain. It also interacts with FGF ligands and 
heparin. However, in contrast to the classical receptors, it does 
not possess any tyrosine kinase activity in the intracellular 
domain and consequently, it cannot signal by transphosphoryla-
tion. It has therefore been speculated that FGFRL1 may function 
as a negatively acting receptor (decoy receptor) that binds and 
neutralizes FGFs (4,5). The intracellular domain of FGFRL1 
harbors a tandem tyrosine motif (YXXΦYXXΦ) and a peculiar 
histidine-rich sequence. Both motifs act as sorting signals, which 
target the receptor to endosomes and lysosomes, and control its 
retention time at the cell membrane (6). It has also been suggested 
that the tyrosine motif may interact with SHP-1 phosphatase and 
induce the activation of ERK1/2 protein in β cells (7).
FGFRL1 must fulfill a crucial function during embryonic 
development, as shown by the fact that FgfrL1 knockout mice die 
during birth with a penetrance of 100% (8,9). When compared 
to their wild-type littermates, the FgfrL1-deficient mice reveal 
a striking phenotype: they lack metanephric kidneys (10), they 
show a malformed diaphragm (8) and they have a dome-shaped 
skull (9). In a recent study, we showed that the alterations of the 
diaphragm are caused by the absence of slow muscle fibers (11). 
Without slow muscle fibers, the diaphragm is too weak to 
inflate the lungs and the mice will die by suffocation within 
minutes after birth.
We have recently compared the expression profiles of tissues 
from wild-type and FgfrL1 knockout mice by gene arrays and 
RT-PCR (12). Unexpectedly, we found that neither of the typical 
target genes of FGF signaling was expressed at higher levels in 
FgfrL1-deficient mice as would be expected after deletion of a 
negatively acting regulator. It is therefore unlikely that FgfrL1 
acts as a decoy receptor, which attenuates FGF signaling. We 
have also produced mice with a targeted disruption of the intra-
cellular domain of FgfrL1 (13). To our surprise, such mice are 
fully viable and do not display any obvious alterations when 
compared to their wild-type littermates. Thus, the intracellular 
domain is dispensable for normal life and most, if not all, of the 
vital functions of FgfrL1 must be conducted by the extracel-
lular domain.
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In this study, we examined the effects of FgfrL1 on cell 
proliferation and FGF signaling. We found that FgfrL1 did not 
affect cell proliferation, but that it promoted cell adhesion. It is 
therefore likely that FGFRL1 is a cell adhesion protein, rather 
than a signaling receptor.
Materials and methods
Cell culture. HEK-TetOn cells were purchased along with the 
advanced TetOn expression system from Clontech Labora-
tories (Takara Bio Europe/Clontech, Saint-Germain-en-Laye, 
France). All other cell lines were obtained from the American 
Type Culture Collection (ATCC, Manassas, VA, USA): 
293 cells (CRL-1573), A204 rhabdomyosarcoma cells (HTB82), 
MG63 osteosarcoma cells (CRL-1427), FaDu squamous 
carcinoma cells (HTB-43) and Detroit 562 pharyngeal carci-
noma cells (CCL-138). The cells were grown under standard 
conditions in Dulbecco's modified Eagle's medium (DMEM) 
supplemented with 10% fetal bovine serum, penicillin (100 U/
ml) and streptomycin (100 µg/ml). For cell adhesion assays, 
the HEK-TetOn cells were cultivated on bacterial (non-tissue 
culture) petri dishes obtained from Sarstedt AG (Nümbrecht, 
Germany) (35 mm, 82.1135) or Falcon (60 mm, 1007; Thermo 
Fisher Scientific AG, Reinach, Switzerland). In some experi-
ments, FGF signaling was stimulated with 15-100 ng/ml of 
human recombinant FGF2 (PeproTech, London, UK and Sino 
Biological, Inc., Beijing, China). The growth and shape of the 
cells were examined under a Nikon E800 eclipse microscope 
(Nikon AG, Elgg, Switzerland)
Generation of tetracycline-inducible cell clones. The 
HEK-TetOn cells were co-transfected with two cDNA plas-
mids. One plasmid contained human full-length FGFRL1 or 
human FGFRL1ΔC (encoding amino acids 1-417) in the pTRE 
expression vector, which harbors a tetracycline responsive 
promoter element. The other was a linearized hygromycin 
selection marker (Clontech). Following transfection, the cells 
were selected with 100 µg/ml hygromycin until resistant 
colonies could be observed (2-4 weeks). Individual colonies 
were isolated with the help of cloning cylinders and expanded. 
Approximately 40 individual cell clones were isolated from 
each transfection experiment. The clones were pre-screened 
for inducible FGFRL1 expression by immunostaining with a 
monoclonal antibody against human FGFRL1 as described 
elsewhere (6). For further cultivation of the stable cell clones, 
hygromycin was used at 60 µg/ml to maintain the selection 
pressure.
Northern blot analysis. Total RNA was isolated from the 
confluent cell cultures with the GenElute miniprep kit from 
Sigma-Aldrich (St. Louis, MO, USA). The RNA was resolved 
on 1% agarose gels in the presence of formaldehyde. The gels 
were stained with ethidium bromide to visualize the 18S and 28S 
ribosomal RNAs. The RNAs were quantitatively transferred to 
a nylon membrane by vacuum blotting. The blot was hybrid-
ized under standard conditions with probes that contained 
full-length cDNAs for FGFRL1 and GAPDH, respectively. 
Beforehand, these probes had been radiolabeled by random 
primed oligolabeling with 32P-dCTP (New England Nuclear/
PerkinElmer, Waltham, MA, USA). The blot was extensively 
washed with 1X SSC and exposed to X-ray film (Carestream 
Kodak BioMax MS; Sigma). For quantification of the bands, 
the blot was scanned with a phosphorimager (Storm 840; 
Molecular Dynamics, Sunnyvale, CA, USA).
Proliferation assay. Cells grown in tissue culture flasks were 
collected by trypsinization and seeded into the wells of 24-well 
plates at a density of approximately 2x104 cells/well. One day 
after seeding, half of the wells was stimulated with 1 µg/ml 
doxycycline, while the other half remained untreated. During 
the following 5 days, the cell number was determined with 
a colorimetric assay that measures the amount of the endog-
enous enzyme hexosaminidase (14). To this end, the media 
were removed from the cell layers by aspiration and 100 µl 
of a solution containing 3.75 mM p-nitrophenyl-N-acetyl-
β-D-glucosaminide, 50 mM sodium citrate, 0.25% Triton X-100, 
pH 5.0 was added to each well. After 45 min, the reaction was 
terminated by the addition of 200 µl of 50 mM glycine, 5 mM 
EDTA, pH 10.4 and the absorbance of the yellow product 
was determined at 405 nm using an Infinite M200 microplate 
reader (Tecan AG, Männedorf, Switzerland).
Western blot analysis. Cell cultures were rinsed with cold 
phosphate-buffered saline (PBS) and directly dissolved in hot 
SDS sample buffer containing 2% mercaptoethanol. Proteins 
were separated under standard conditions on 10% SDS 
polyacrylamide gels containing 5% stacking gels. Resolved 
polypeptides were transferred from the gels to nitrocellulose 
membranes by semi-dry blotting (Trans-Blot SD; Bio-Rad 
Laboratories, Hercules, CA, USA). Unspecific sites of the 
membranes were blocked with 3% milk powder in PBS. The 
membranes were incubated with affinity-purified antibodies 
against phosphorylated human ERK1/2 (E7028, 1:1,000; 
Sigma). After 12 h, the membranes were rinsed with PBS and 
incubated for 2 h with phosphatase-conjugated secondary anti-
bodies (711-055-152; Jackson ImmunoResearch Laboratories, 
West Grove, PA, USA). Bound antibodies were detected by 
reaction with 5-bromo-4-chloro-3-indolyl-phosphate and 
nitroblue tetrazolium substrate. After stripping, the blots were 
stained in a similar way with a monoclonal antibody against 
total p42/44 MAP kinase (L34F12; 1:2,000; Cell Signaling 
Technology Inc., Danvers, MA, USA).
Kinexus antibody microarrays. Protein extracts were prepared 
from HEK-TetOn cells grown on 10 cm tissue culture plates 
in the presence or absence of the inducer, doxycycline. 
Special care was taken to ensure that the two samples were 
always treated in parallel in the same way. The cell layers 
were rinsed with ice-cold PBS and lysed with 0.2 ml lysis 
buffer containing 20 mM MOPS, 1% Triton X-100, pH 7.0 
and proteinase and phosphatase inhibitors as suggested by 
Kinexus Bioinformatics Corp. (Vancouver, BC, Canada). To 
rupture the cell bodies, the suspensions were sonicated twice 
for 15 min with an ultrasonic processor (Sonics Vibra-Cell; 
Sonics & Materials, Inc., Newtown, CT, USA). The homog-
enates were cleared in a Centrikon T-2170 ultracentrifuge at 
100,000 x g for 30 min. Subsequently, the clear homogenates 
were analyzed on Kinex Antibody Microarrays (KAM-1.1; 
Kinexus Bioinformatics Corp.) that contained >650 different 
antibodies against signaling proteins. Selected proteins were 
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further verified by the Kinetworks multi-immunoblotting 
service.
Downregulation by siRNA. The expression of FGFRL1 was 
downregulated with siRNA oligonucleotides from Dharmacon 
(ON-TARGETplus SMARTpool siRNA; Thermo Fisher 
Scientific, Waltham, MA, USA). To target the human FGFRL1 
mRNA, a pool of the following four oligonucleotides was 
utilized: GGCUGAAGCGCGUGGAGUA, GGACACUGAG 
CCUGAAGAA, GCUCCUACCUCAAUAAGCU and GAA 
CACGACGGUGGACUUC. As a control, a pool of four non- 
targe ting oligonucleotides was used (D-001810-10-05). To 
form lipid complexes, the oligonucleotides were mixed with 
Lipofectamine 2000 reagent in Opti-MEM medium (Invitrogen 
Life Technologies, Inc., Carlsbad, CA, USA) and incubated for 
5 min at room temperature. The complexes were added 
dropwise to the cells grown either in 35 mm dishes (for northern 
blot analysis) or 24-well plates (for proliferation assays) at a 
final concentration of 25-50 nM.
Results
Effect on cell proliferation. To measure the effects of FGFRL1 
on cell growth and proliferation, and to avoid problems of repro-
ducibility that are frequently observed by transient transfection 
experiments, we used a stable, tetracycline-inducible expres-
sion system. Commercially available HEK-TetOn cells, which 
constitutively express the Tet transactivator protein, were stably 
transfected with two different tetracycline-inducible FGFRL1 
constructs, namely the human wild-type construct FGFRL1 
and the human construct FGFRL1ΔC, which lacks the intracel-
lular domain (Fig. 1A). Following selection with antibiotics, 
colonies were isolated and pre-screened for FGFRL1 expres-
sion by immunostaining with an antibody against FGFRL1. 
Positive clones were further checked for strong inducibility of 
FGFRL1 expression by northern blot analysis (Fig. 1B and C). 
Clones with a relatively high induction of FGFRL1 expression 
and relatively low background expression before the addition of 
doxycycline were selected for further experiments (full-length 
clones: K3F, K5F, K9F, K17F, K19F, K24F; truncated clones 
FGFRL1ΔC: K13ΔC, K14ΔC, K33ΔC, K35ΔC, K41ΔC). In 
the following, we will describe several experiments performed 
with these clones and present data for some selected clones. 
However, it should be emphasized that most experiments were 
performed with all of the clones and that we never observed 
any qualitative differences among the clones.
On a northern blot analysis, our clones showed a relatively 
tight repression before, but a relatively strong expression of 
FGFRL1 after the addition of the inducer, doxycycline (Fig. 1B 
and C). Nevertheless, when the blot was overexposed, bands 
corresponding to the FGFRL1 mRNA could also be detected 
in the lanes without doxycycline, suggesting that our expres-
sion system showed some leakiness. The extent of inducibility 
was determined by quantification of the northern blotting with 
the help of a phosphorimager. Clone K17F could be induced 
>180-fold, and clone K24F >30-fold.
A slight heterogeneity was noted between the individual clones 
with respect to the length of the mRNAs. This heterogeneity may 
originate from different sizes of the 3'UTR and the poly(A) tract 
due to integration of the cDNA constructs at different sites in 
the genome. In two selected cases (K17F, K13ΔC) we subcloned 
the expressed cDNA by RT-PCR and fully confirmed the open 
reading frame of the FGFRL1 sequence.
Fig. 2 shows two examples of FGFRL1 expression in 
cell culture by immunofluorescence with a monoclonal anti-
body against human FGFRL1. In the absence of the inducer 
doxycycline, no expression was observed. In the presence of 
doxycycline, a strong fluorescent signal was observed, indicating 
strong inducibility of FGFRL1 expression. As expected, the fluo-
rescent signal was predominantly found at the cell membrane 
in the case of the FGFRL1ΔC construct (K13ΔC), but mainly 
in intracellular compartments in the case of the full-length 
construct (K3F). As previously reported, this difference in the 
distribution of the expressed protein is explained by the presence 
or absence of two sorting signals in the transfected FGFRL1 
constructs (6). Thus, we have successfully generated cell lines, in 
which we can overexpress FGFRL1 by 30 to 180-fold.
Figure 1. Generation of HEK-TetOn cell lines with tetracycline-inducible fibro-
blast growth factor receptor-like protein 1 (FGFRL1) expression. (A) Schematic 
representation of the two FGFRL1 constructs that were stably transfected into 
HEK-TetOn cells. FGFRL1 represents the full-length, wild-type receptor, while 
FGFRL1ΔC contains a truncated C-terminal domain lacking the histidine-rich 
sequence and the tandem tyrosine motif. The two motifs are known to control 
the retention time of the receptor at the cell membrane. Hygromycin resistant 
cell clones were analyzed by northern blotting for inducible FGFRL1 expres-
sion. (B) Three representative full-length clones and (C) three representative 
C-terminally truncated clones are shown before and after induction with 1 µg/
ml doxycycline. As a loading control, the 28S ribosomal RNA stained with 
ethidium bromide is included.
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The inducible TetOn clones were utilized to examine the 
effects of FGFRL1 on cell proliferation. Individual clones were 
seeded on cell culture plates and grown for up to 5 days in the 
presence or absence of the inducer, doxycycline. As shown in 
Fig. 3, the addition of doxycycline at 1 µg/ml had absolutely no 
effect on cell growth. Albeit we noted a slight difference in the 
growth curves between individual clones, a given clone always 
showed the same growth characteristics in the absence or pres-
ence of doxycycline. This observation was true for full-length 
clones (e.g., clones K3F, K19F) as well as for C-terminally trun-
cated clones (e.g., clones K13ΔC, K33ΔC). Thus, the presence 
of FGFRL1 does not appear to have any effect on cell growth, 
at least not on the proliferation of our HEK-TetOn cells.
We also tried to prepare other stable cell lines (HT1080, 
A204) that would express FGFRL1 in an inducible manner. 
However, we failed to obtain any other stable cell clones. This 
finding is in keeping with the remarks of the distributor of the 
TetOn expression system that it is extremely difficult to select 
cell lines, which stably express the Tet transactivator protein.
ERK1/2 signaling. Since we had expected that FGFRL1 
would be involved in FGF signaling, we examined the effects 
of FGFRL1 on the activation of the MAP/ERK signaling 
pathway. These experiments were conducted only with the full-
length clones, K3F, K5F, K17F K19F and K24F, which possess 
an intact intracellular domain. The clones were grown on cell 
culture plates for 1-2 days in the presence of fetal bovine serum, 
starved overnight and then stimulated with FGF2 at 15 ng/ml 
or 30 ng/ml (a concentration of 15 ng/ml has a maximal effect 
on ERK phosphorylation according to a previous publica-
tion) (15). At the same time, half of the cultures were treated 
with doxycycline to induce the expression of FGFRL1, while 
the other half were left untreated. After different time inter-
vals, the cell layers were dissolved in SDS sample buffer and 
analyzed by western blotting with specific antibodies against 
phosphorylated ERK (Fig. 4A). Before the addition of FGF2, 
the level of phosphorylated ERK of our HEK-TetOn cells 
was below the detection level. After the addition of FGF2, 
we observed two faint bands that should correspond to phos-
phorylated ERK1 and ERK2. Most importantly, we did not 
observe any differences in the levels of phosphorylated ERK 
between cultures grown in the absence or the presence of the 
inducer, doxycycline. To verify that our samples contained 
equal amounts of unphosphorylated ERK, we treated the same 
western blot after stripping with an antibody to total ERK. Two 
bands corresponding to ERK1 and ERK2 were observed and 
these bands had similar intensities in the samples before and 
after doxycycline treatment. Thus, the expression of FGFRL1 
did not appear to have any effect on ERK1/2 signaling.
Since the ERK signal detected in Fig. 4A was rather faint, 
we transfected a full-length clone for FGFR1 into our cell 
lines in order to enhance FGF signaling. In fact, we were 
able to increase the ERK signal significantly by this treat-
ment (Fig. 4B). At the beginning of the experiment (0 min), 
no ERK phosphorylation was detected, but 5 and 15 min after 
FGF stimulation, the bands of phosphorylated ERK1/2 became 
much stronger than in the experiment without FGFR1 transfec-
tion. Nevertheless, we could not detect any differences in ERK 
phosphorylation between cultures grown in the presence or 
absence of doxycycline.
Kinexus antibody microarray. Since FGFRL1 may also affect 
a pathway other than ERK signaling, we subjected two selected 
clones (K3F, K17F) to a global analysis of signaling proteins. As 
Figure 2. Inducible expression of fibroblast growth factor receptor-like protein 1 (FGFRL1) demonstrated by immunofluorescence. A representative full-length 
clone (K3F) and a representative truncated clone (K13ΔC) were cultivated in the presence (plus Dox) or absence (minus Dox) of the inducer doxycycline. 
Expression was visualized with a monoclonal antibody against human FGFRL1. Note that the wild-type receptor resided primarily in intracellular compart-
ments, while the truncated form accumulated at the plasma membrane.
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above, the cells were grown for 32 h in the presence or absence 
of the inducer doxycycline and protein extracts were prepared 
according to an established protocol. The extracts were analyzed 
by the Kinexus antibody microarray service, which utilizes 
>650 verified antibodies against most well-studied signaling 
proteins, including phospholipase Cγ, PI3-kinase, STAT and 
Akt. Differences in the absolute amount of the signaling 
proteins (using 380 pan-specific antibodies), as well as differ-
ences in their phosphorylation status (using 270 phospho-site 
specific antibodies) were investigated. To our surprise, we did 
not find any significant differences between the doxycycline-
treated and untreated cell cultures. Nevertheless, 18 proteins that 
had shown slight (but not significant) changes between the two 
culture conditions were selected for further investigation. To this 
end, the two protein extracts were subjected to western blotting 
with a set of specific, verified antibodies against the 18 signaling 
proteins. However, as demonstrated by the immunoblot of Fig. 5, 
we could not detect any significant differences in the absolute 
amount or in the phosphorylation status of the selected signaling 
proteins. Thus, the expression of FGFRL1 in our cell clones did 
not appear to have any major effect on the signaling pathways 
that are covered by the Kinexus antibody microarray.
Downregulation of FGFRL1 expression by siRNA. As 
mentioned before, our doxycycline-inducible FGFRL1 TetOn 
clones show, in addition to their strong inducibility, a low 
level of leakiness. If a low level of FGFRL1 expression would 
already elicit a full response, we would not see any additional 
effect upon the overexpression of FGFRL1. To tackle this 
problem, we performed a set of converse experiments, in 
which we tried to downregulate FGFRL1 expression. For this 
purpose, we selected three different cell lines that express 
either low levels of FGFRL1 (293 kidney cells), moderate 
levels of FGFRL1 (A204 rhabdomyosarcoma cells) or rela-
tively high levels of FGFRL1 (MG63 osteosarcoma cells), as 
demonstrated by northern blotting with a probe for human 
FGFRL1 (Fig. 6A). A pool of siRNA oligonucleotides was 
obtained from Dharmacon, which should effectively downreg-
ulate FGFRL1 mRNA levels following transfection into cells. 
In fact, when used at 25 nM, these oligonucleotides decreased 
Figure 3. Effect of fibroblast growth factor receptor-like protein 1 (FGFRL1) 
expression on cell proliferation. Stable HEK-TetOn clones were cultivated in 
the presence or absence of doxycycline in 24-well plates. Cell proliferation was 
measured over the course of five days with the hexosaminidase assay. No effect 
on cell proliferation was observed by the presence of FGFRL1 or FGFRL1ΔC. 
Standard errors are given at some time-points where meaningful (n=3).
Figure 4. Effect of fibroblast growth factor receptor-like protein 1 (FGFRL1) on 
ERK phosphorylation. FGFRL1 inducible HEK-TetOn cells were cultivated in 
multi-well plates, starved overnight in medium lacking fetal bovine serum and 
then stimulated for 0-60 min as indicated with human FGF2 (15 ng/ml). Cells 
were lysed with hot SDS sample buffer. Cellular proteins were resolved on 
polyacrylamide gels and processed for western blotting with antibodies against 
phosphorylated ERK1/2 (ERK-p). The blots were stripped and reprobed with 
antibodies against total ERK (ERK-tot). An experiment conducted with clone 
K24F is depicted in panel A. Panel B shows an experiment with clone K17F. 
However in this case, the cells had been transfected - prior to starvation and 
FGF2 stimulation - with a full-length clone for human FGFR1 to increase 
signaling. ERK1/2 phosphorylation was extremely low before stimulation, but 
clearly visible after stimulation with FGF2. No difference in ERK phosphory-
lation was observed between doxycycline-induced and uninduced cells.
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FGFRL1 levels in the 293, A204 and MG63 cells by 75-84%, 
as demonstrated by northern blotting and quantification with 
a phosphorimager (Fig. 6B). However, the same siRNA oligo-
nucleotides had no effect on the levels of the GAPDH mRNA 
or 28S RNA. Likewise, a pool of control RNA oligonucleotides 
had no effect on the level of the FGFRL1 mRNA, demon-
strating the specificity of the FGFRL1 siRNA pool.
Cell proliferation was determined by the hexosaminidase 
assay two days following transfection of the siRNAs or control 
RNAs into the three cell types. Although the siRNA pool had 
downregulated FGFRL1 mRNA levels to near zero, we did not 
detect any changes in the proliferation rate of the 293, A204 
and MG63 cells (Fig. 7A). Obviously, the downregulation of the 
FGFRL1 mRNA had no significant effect on cell proliferation.
Recently, another research group reported that FGFRL1 
would have a stimulatory effect on the proliferation of 
certain tumor cells (16,17). These authors studied primary 
and established cell lines derived from human esophageal 
squamous cell carcinoma (ESCC). We therefore extended 
our siRNA experiments on esophageal squamous carcinoma 
cells. As before, we used a cell line that expressed low levels 
of FGFRL1 (FaDu cells) and another cell line that expressed 
relatively high levels of FGFRL1 (Detroit 562 cells) as assessed 
by northern blotting (Fig. 6C). When our pool of siRNA 
Figure 5. Kinexus antibody microarray. Fibroblast growth factor receptor-like 
protein 1 (FGFRL1) inducible cells (clone K3F) were cultivated for 32 h in the 
presence or absence of the inducer doxycycline. Protein extracts were prepared 
and analyzed on Kinexus antibody microarrays containing more than 650 dif-
ferent antibodies against various signaling proteins. No significant differences 
were observed between doxycycline-treated and untreated cells (not shown). 
To verify some of the results, the two protein extracts were separated on SDS 
polyacrylamide gels, transferred to an immunoblot membrane and probed with 
antibodies against 18 selected proteins as indicated using a multiscreen appa-
ratus from BioRad. The immunoblot was analyzed with a chemiluminescence 
imager. No significant differences were observed between doxycycline-
induced (lower panel) and uninduced (top panel) cells. The migration positions 
of molecular weight markers are shown in the left and right margins by short 
horizontal lines. These lines correspond (from top to bottom) to 250 K, 150 K, 
100 K, 75 K, 50 K, 37 K, 25 K, 20 K and 15 K.
Figure 6. Downregulation of fibroblast growth factor receptor-like pro-
tein 1 (FGFRL1) by siRNA oligonucleotides. (A) A northern blot demonstrates 
the levels of FGFRL1 mRNA in three different cell lines. Osteosarcoma 
cells (MG63) express relatively high levels of FGFRL1, A204 rhabdomyo-
sarcoma cells moderate levels and 293 cells very low levels. (B) The cells 
were transfected with a pool of siRNA oligos against FGFRL1 or with con-
trol RNA oligos. In each of the three cell lines, the FGFRL1 mRNA levels 
were downregulated to near zero, while the levels of GAPDH and 28S RNA 
remained unaffected. (C) An analogous experiment was performed with two 
cell lines from esophageal cell carcinomas. Detroit 562 cells express mod-
erate levels of FGFRL1, FaDu cells extremely low levels. In both cases, the 
FGFRL1 levels could be downregulated to near zero with siRNA oligos.
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oligonucleotides was transfected into these cells, we observed 
a downregulation of FGFRL1 mRNA levels to nearly zero. 
However, cell proliferation, measured by the hexosaminidase 
assay, did not significantly differ between doxycycline-treated 
and untreated cells after two days in culture (Fig. 7B). Thus, it 
is very unlikely that FGFRL1 has any stimulatory effect on the 
proliferation of our esophageal tumor cells.
Cell adhesion. If FGFRL1 does not have any effect on cell 
growth and proliferation, it would be of interest to determine 
what function it has, if any. We have previously observed that 
recombinant FGFRL1 induced cell adhesion when coated on 
bacterial plastic dishes (18).
We therefore investigated whether the inducible expression 
of FGFRL1 in our HEK-TetOn cells would have any effect on 
cell adhesion. To this end, our cell clones were seeded into 
untreated (bacterial) petri dishes and grown in the absence 
or presence of the inducer, doxycycline. Cell adhesion was 
inspected under a microscope 10-15 h after seeding. As demon-
strated in Fig. 8, neither of the cell lines was able to attach to 
the bacterial plastic plates in the absence of doxycycline within 
this short period of time. However in its presence, the cells 
began to attach to the plastic surface and to spread. Moreover, 
they aggregated and began to form large clusters, probably by 
cell-cell adhesion. This adhesion and clustering phenomenon 
was observed with the full-length clones as well as with the 
C-terminally truncated clones. A slight difference was noted 
between individual clones in the extent of clustering. This 
difference may reflect different amounts of FGFRL1 protein 
synthesized by individual cell clones within a given period of 
time. After 24 h, the differences between doxycycline-treated 
and untreated cells were no longer dramatic and the cells 
began to attach and cluster also in the absence of doxycycline. 
This may be explained by the leakiness of inducible FGFRL1 
expression and/or by the synthesis of adhesive proteins other 
than FGFRL1 (fibronectin, collagen, NCAM). Nevertheless, 
our experiments show that FGFRL1 has a clear effect on cell 
adhesion during the initial hours after seeding.
Discussion
In the present study, we presented compelling evidence that 
the novel receptor, FGFRL1, does not control cell growth and 
proliferation, but that it rather exerts a positive effect on cell 
adhesion. This conclusion was drawn from various experi-
mental appro aches, including: i) the inducible overexpression 
of FGFRL1 in HEK-TetOn cells; ii) the downregulation of 
FGFRL1 by siRNA oligonucleotides in established cell lines; 
iii) the determination of ERK phosphorylation in the presence 
and absence of FGFRL1; iv) the analysis of 650 signaling mole-
cules by Kinexus antibody microarrays; and v) cell adhesion 
on bacterial petri dishes upon induction of FGFRL1 synthesis. 
Originally, we as well as other researchers had expected that 
FGFRL1 would have a negative effect on cell growth as it 
interacts with growth factors of the FGF family but cannot 
signal by phosphorylation as it lacks the intracellular tyro-
sine kinase domain (5,19). The interaction with FGF ligands 
has been confirmed in different laboratories using various 
approaches, such as coprecipitation, dot blot assays, cell-based 
ligand binding assays and surface plasmon resonance, and it 
was found that FGFRL1 mainly interacted with FGF3 and 
FGF8 (3). Obviously, we must face the fact that this interaction 
does not trigger cell proliferation. Nevertheless, the new find-
ings are compatible with the domain structure of FGFRL1 as 
Figure 7. Effect of fibroblast growth factor receptor-like protein 1 (FGFRL1) downregulation on cell proliferation. Expression of FGFRL1 was downregulated 
with siRNA oligos in different cells lines as indicated and cell proliferation was measured with the hexosaminidase assay after two days. The results are 
expressed relative to a control treated with unrelated RNA oligos (100%). The bars indicate standard errors from four independent samples. No differences in 
cell proliferation were noted between control and FGFRL1 downregulated cells.
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this receptor is lacking the intracellular tyrosin kinase domain 
that would be required for phosphorylation. The new findings 
are also in accordance with the observation that genetically 
manipulated mice with a deletion of the intracellular domain of 
FgfrL1 are viable and do not exhibit any abnormal phenotype 
when compared with wild-type littermates (13). Obviously, the 
intracellular domain of FGFRL1 is dispensable for survival.
The only definite effect of FGFRL1 that we could document 
in our study was a positive influence on cell adhesion. Upon 
expression of FGFRL1 in our inducible HEK-TetOn clones, the 
cells started to aggregate and to form large clusters. Without 
FGFRL1 induction, no similar clustering was observed. 
However, the effect was detected only during the initial hours 
after cell seeding and after two days, we did not notice any 
differences between FGFRL1 induced and uninduced cell 
cultures. It is possible that after two days, other cell adhesion 
molecules, such as fibronectin, collagen and NCAM, have taken 
over the adhesive function of FGFRL1. Furthermore, the effect 
could not be demonstrated with surface-treated culture dishes 
that are normally utilized for cell culture experiments. A critical 
function of FGFRL1 in cell adhesion is compatible with our 
previous observations that FGFRL1 can bind to heparin and 
to heparan sulfate proteoglycans on cell surfaces (18). At that 
time, we showed that the second Ig domain was responsible for 
the heparin-binding activity and that it could be blocked with 
soluble heparin as well as with heparin-binding peptides.
An important function of FGFRL1 in cell-cell adhesion 
had already been suggested by our studies with knockout 
Figure 8. Effect of fibroblast growth factor receptor-like protein 1 (FGFRL1) on cell adhesion. FGFRL1 inducible HEK-TetOn cells were seeded into bacte-
rial (non-tissue culture) petri dishes and cultivated for 10-15 h in the absence (minus) or presence (plus) of the inducer doxycycline. Note that expression of 
FGRL1, in its full-length form as well as its truncated form, promoted cell-cell adhesion and cell clustering. In sharp contrast, most cells remained in their single-
cell state in the absence of FGFRL1 within this short period of time. A control with original HEK-TetOn cells (prior to transfection with FGFRL1 constructs) 
did not show any differences between the two conditions.
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mice. FgfrL1-null mice lack metanephric kidneys because the 
metanephric mesenchyme is not able to undergo the essential 
conversion into the nephrogenic epithelium (10). Obviously, 
FgfrL1 must be expressed at the cell surface of mesenchymal 
cells in order to induce proper alignment and tight cell clustering 
as required for differentiation into renal epithelium. A similar 
effect was also noticed in the diaphragm. FgfrL1 knockout 
mice die because their diaphragm is too weak to inflate the 
lungs after birth (8,11). During development of the diaphragm 
muscle, individual muscle precursor cells must align with each 
other in order to fuse into myotubes and myofibers. Obviously, 
FGFRL1 is required at the cell surface of muscle precursor 
cells to initiate such an alignment.
A critical function in cell adhesion is also in keeping with 
our observations that FGFRL1 can induce cell-cell fusion in 
culture. With CHO cells and similar cell types, the mere over-
expression of FGFRL1 leads to fusion of the cells into large 
syncitia containing several dozens of nuclei (20). It is unlikely 
that this fusogenic activity is a normal, physiological function of 
FGFRL1, as it is not observed with other cell types. However, it 
demonstrates that FGFRL1 can pull together two cell surfaces 
with high tensile strength. In a recent publication, we have 
found evidence that FGFRL1 binds to a target molecule on 
neighboring cells to induce cell-cell fusion (21). A hydrophobic 
pocket in the third Ig domain of FGFRL1 appeared to interact 
with this target protein. However, the identity of the target 
protein remained elusive.
With its domain structure and its function during cell 
adhesion, FGFRL1 resembles another family of proteins, the 
nectins (22,23). Four different nectins (nectin-1 to nectin-4) 
have been identified that possess a domain structure similar to 
FGFRL1 with three extracellular Ig domains, a single trans-
membrane domain and a relatively short intracellular domain. 
The nectins are involved in cell-cell adhesion and immune 
modulation and play an important role during host-pathogen 
interactions. The adhesive function is accomplished by homo-
philic as well as heterophilic interactions of the nectins. During 
the adhesive process, the C-terminal cytoplasmic domain is 
required to remodel the actin cytoskeleton. It interacts with 
the PDZ domain of the adapter molecule afadin, which in 
turn recruits filamentous actin. So far, we do not have any 
evidence that FGFRL1 would interact with afadin or with any 
of the four nectins. Furthermore, the C-terminal domain of 
FGFRL1 appears to be dispensable for its function (13). Thus, 
the molecular mechanism of inducing cell adhesion must be 
quite different between FGFRL1 and the nectins, although the 
proteins share structural and functional homology.
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